F105 The Future of Dermatology: What Changes Are Coming and How Can We Prepare?
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
The session will focus on the latest events and advocacy updates post the Covid 19 pandemic in Dermatology. Issues including title misappropriation, scope of practice and truth in advertising, issues with private insurers/Medicare, access to prescription medication/OTC products, AI updates, and ensuring diversity in dermatology will be discussed.
LEARNING OBJECTIVES
Assess resources to manage your practice optimally in our post pandemic practice environment.
Adapt strategies to navigate numerous rapidly changing regulatory rules affecting our ability to deliver patient care in the setting of the post pandemic new normal.
As Board Certified/Eligible Dermatologists and leaders of the Dermatology Care Team, anticipate the future of Dermatology post pandemic embracing strategies to ensure patient safety, truth in advertising, and maintaining standards of care.
SCHEDULE
8:00 PM
Opening Remarks 1 to 1:10
Sabra Sullivan, MD, PhD, FAAD
8:10 PM
AI Update
Ross Lane Pearlman, MD, FAAD
8:30 PM
Advocacy
Jon Klint Peebles, MD, FAAD
8:50 PM
Update State of the Specialty
Brett M. Coldiron, MD, FAAD
9:20 PM
Upstate State and Federal Affairs, Insurance Landscape
Sabra Sullivan, MD, PhD, FAAD
9:40 PM
Questions and Discussion
SPEAKERS
Brett M. Coldiron, MD, FAAD
Ross Lane Pearlman, MD, FAAD
Jon Klint Peebles, MD, FAAD
Sabra Sullivan, MD, PhD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Brett M. Coldiron, MD, FAAD
No financial relationships exist with ineligible companies.
Ross Lane Pearlman, MD, FAAD
Castle Biosciences – Advisory Board(Honoraria); Suneco Technologies – Founder(Stock);
Jon Klint Peebles, MD, FAAD
Kaiser Permanente – Employee(Salary);
Sabra Sullivan, MD, PhD, FAAD
Almirall – Investigator(Grants/Research Funding);